Bloomberg · Rebecca Torrence ·

Warp Sciences, founded by former OpenAI CPO Kevin Weil to speed up drug development using AI, emerges from stealth with $215M at an $865M post-money valuation

Kevin Weil, the former OpenAI executive who led the ChatGPT maker's AI-for-science efforts, is launching a new startup aimed …

OpenAI AI Biotech Venture Capital

In this story Kevin Weil OpenAI Warp Sciences

Warp Sciences, founded by former OpenAI CPO Kevin Weil to speed up drug development using AI, emerges from stealth with $215M at an $865M post-money valuation

Lead Source

Bloomberg — Warp Sciences, founded by former OpenAI CPO Kevin Weil to speed up drug development using AI, emerges from stealth with $215M at an $865M post-money valuation ↗

How this story grew

Coverage · 11 Discussion · 6

4:30 PM9:02 PM UTC

More

TechCrunch: TechCrunch

VC News Daily: VC News Daily

Pulse 2.0: Pulse 2.0

Lightspeed Venture Partners: Lightspeed Venture Partners

Discussion

Stu Smith Rebecca Torrence JP Patil

@kevinweil @kevinweil @dyett

Related stories

Business Insider: Former OpenAI Chief Product Officer Kevin Weil is aiming to raise $150M for a new AI science startup, seeking a valuation of at least $750M

The Information: Wafer, which makes AI agents that optimize open-source models for a business's workload, raised a $40M Series A, a source says at a $200M+ valuation

Bloomberg: Isomorphic Labs, an AI drug discovery startup spun out of Google DeepMind, is in early talks to raise funds at a valuation of at least $40B

GamesBeat: Astromech, which uses genomic data to build predictive AI models of biological change, raised $20M at a $3.8B valuation, bringing its total funding to $60M

Reuters: Shanghai-based Anew Labs, a ByteDance spinoff using AI for drug discovery, raised $290M from HSG, IDG Capital, and others at a $1.5B valuation

Discuss with AI

ChatGPT ↗ Claude ↗

← Back to TechSnif